EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 4.0

Pegfilgrastim versus filgrastim for chemo-mobilized stem cell collection in multiple myeloma: A retrospective real-world study

Yan-Lin Zhang, Xin-Yi Qin, Chun Cao, Zhi-Ming Luo, Ying Zhang, Han-Qing Zeng, Jian-Chuan Deng, Yun Luo

Cancer Treatment and Research Communications · 2026

DOI: 10.1016/j.ctarc.2026.101263 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Cancer Treatment and Research Communications, 2026. Verfasst von Yan-Lin Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The Second Affiliated Hospital of Chongqing Medical University, 76 Linjiang Road, Chongqing 400010, China. Hauptthemen laut MEDLINE: Multiple Myeloma, Filgrastim, Polyethylene Glycols, Hematopoietic Stem Cell Mobilization. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Autologous stem cell transplantation (ASCT) is a standard treatment for newly diagnosed multiple myeloma (MM). Achieving sufficient stem cell yield via effective mobilization promotes successful hematological reconstitution. However, clinical evidence regarding the comparative outcomes of pegfilgrastim (PEG) versus filgrastim (FIL) remains controversial, lacking regimen-specific comparisons. OBJECTIVE: To evaluate the efficacy, safety, efficiency, and costs of PEG versus FIL in MM patients, and compare the impact of cyclophosphamide-based chemo-mobilization on these outcomes. STUDY DESIGN: This single-center retrospective study included 102 MM patients (PEG: n = 49; FIL: n = 53). Primary endpoints were CD34⁺ cell yield, mobilization success, duration, and time to engraftment. Statistical analyses included propensity score matching (PSM), overlap weighting (OW), and subgroup analysis. RESULTS: In the overall cohort, PEG and FIL showed equivalent median CD34⁺ yields (3.90 vs. 4.99 × 10⁶/kg, P = 0.096), mobilization success rates, and total hospitalization costs (P = 0.53). FIL yielded a higher total mononuclear cell count (P < 0.001). Subgroup analysis revealed PEG reduced mobilization duration (10 vs. 15 days, P < 0.001) and sessions in chemo-mobilization. PSM showed comparable yields and engraftment. To address PSM sample attrition and balance covariates, OW was utilized, further confirming that PEG significantly shortened overall duration (P = 0.04) and reduced sessions (P = 0.02). Both regimens exhibited similar engraftment kinetics and safety. CONCLUSION: Both PEG and FIL demonstrate equivalent efficacy for stem cell mobilization in MM. PEG offers superior efficiency by shortening duration and reducing sessions without increasing the total economic burden.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaFilgrastimPolyethylene GlycolsHematopoietic Stem Cell MobilizationHumansRetrospective StudiesFemaleMaleMiddle AgedAgedRecombinant ProteinsTransplantation, AutologousGranulocyte Colony-Stimulating FactorCyclophosphamideAdultTreatment OutcomeHematopoietic Stem Cell Transplantation

Stichwörter der Autor:innen

FilgrastimMultiple myelomaPegfilgrastimStem cell mobilization

Substanzen

FilgrastimpegfilgrastimPolyethylene GlycolsRecombinant ProteinsGranulocyte Colony-Stimulating FactorCyclophosphamide

Autor:innen und Institutionen

  • Department of Hematology, The Second Affiliated Hospital of Chongqing Medical University, 76 Linjiang Road, Chongqing 400010, China.
  • Department of Hematology, The Second Affiliated Hospital of Chongqing Medical University, 76 Linjiang Road, Chongqing 400010, China. Electronic address: 300333@cqmu.edu.cn.

Zitieren

APA

Zhang, Y. L., Qin, X. Y., Cao, C., Luo, Z. M., Zhang, Y., Zeng, H. Q., Deng, J. C., & Luo, Y. (2026). Pegfilgrastim versus filgrastim for chemo-mobilized stem cell collection in multiple myeloma: A retrospective real-world study. Cancer Treatment and Research Communications. https://doi.org/10.1016/j.ctarc.2026.101263

Vancouver

Zhang YL, Qin XY, Cao C, Luo ZM, Zhang Y, Zeng HQ, et al. Pegfilgrastim versus filgrastim for chemo-mobilized stem cell collection in multiple myeloma: A retrospective real-world study. Cancer Treatment and Research Communications. 2026. doi:10.1016/j.ctarc.2026.101263

BibTeX
@article{Zhang2026,
  author = {Zhang, Yan-Lin and Qin, Xin-Yi and Cao, Chun and Luo, Zhi-Ming and Zhang, Ying and Zeng, Han-Qing and Deng, Jian-Chuan and Luo, Yun},
  title = {Pegfilgrastim versus filgrastim for chemo-mobilized stem cell collection in multiple myeloma: A retrospective real-world study},
  journal = {Cancer Treatment and Research Communications},
  year = {2026},
  doi = {10.1016/j.ctarc.2026.101263}
}
Kostenlos starten →